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Objective
Dendritic cell (DC)-based cancer vaccines may have a
significant benefit to patients with advanced non-small cell
lung cancers (NSCLCs). However, variations among clini-
cal studies make it difficult to compare clinical outcomes.
J-SICT DC vaccine study group is composed of the multi-
medical centers in Japan, has provided DC vaccines as a
compassionate use under the unified regimens for cell
production and patient treatment, and published a num-
ber of clinical data of patients treated with DC vaccines.
A single medical institution of this group has recently pub-
lished a potentially beneficial effect of DC vaccines on
overall survival of 62 patients with advanced NSCLCs[1].
Here we extended the findings to 260 patients with
advanced NSCLCs who treated among 6 centers of this
group.
Methods
Of 337 patients who met the inclusion criteria, 260
patients who received by weekly more than 5-times of
peptide-pulsed DC vaccines were analyzed.
Results
No serious adverse event related to DC vaccination. The
mean survival time from diagnosis was 33.0 months (95%
CI=27.9–39.2, 85.5% in 1-year and 66.4% in 2-years), and
that from the first vaccination was 13.8 months (95%
CI=11.4–16.8, 53.5% in 1-year and 36.1% in 2-years).
Similar to our previous findings obtained in the analysis
for advanced pancreatic cancer[2], 30 mm and more in
diameter of erythema reaction at the injected site was
identified as the strongest factor correlating to the overall
survival from 1st vaccine (> 30 mm: MST=20.4 months,
n=135 and < 30 mm: MST=8.8 months, n=122, p <
0.0001) in uni- and multivariate analyses. Importantly, the
size of erythema reaction was significantly correlated with
ECOG-PS, neutrophil/lymphocyte (N/L) ratio, hemoglo-
bin, C-reactive protein, and fever (over 38 oC) at the time
of leukapheresis, suggesting that the good physical condi-
tion as well as less inflammatory reaction might be impor-
tant to induce stronger reaction against DC vaccines.
Conclusions
This is the first report of a multicenter clinical study
suggesting the feasibility and possible clinical benefit of
DC vaccines in patients with advanced NSCLCs. These
findings suggest the potential responders against DC
vaccines, and need to be addressed in well-controlled
prospective randomized trials.
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